cell number (% vehicle control)

1. Supplementary Fig. S1 Box et al. A) B) cell number (% vehicle control) cell number (% vehicle control) gefitinib concentration (µM) cisplatinconcentration (µM) D) S R S2 R2 C) control EGFR P-EGFR total EGFR sensitive cell number P-AKT total AKT resistant cell number P-ERK 1/2 total ERK 1/2 101 102 103 expression level (fluorescence intensity) GAPDH F) E) 100 75 50 25 0 100 75 50 25 0 sensitive resistant % cells % cells 0.0 0.1 1.0 0.0 0.1 1.0 gefitinib concentration (µM) gefitinib concentration (µM)

2. Supplementary Fig. S2 Box et al. A) B) cell number (% 0 h) tumour volume (cm3) time (hours) time (days)

3. Supplementary Fig. S3 Box et al. A) B) 450 400 350 300 250 200 150 100 50 0 gefitinib-treated tumour volume (% day 0) gefitinib-treated tumour volume (% vehicle-treated) CALSCALR CALS2 CALR2 time (days of therapy)

4. Supplementary Fig. S4 Box et al. A) Resistance Log2 ratio of resistant/sensitive expression Sensitivity CALRonly B) β expression level (arbitrary units)

5. Supplementary Fig. S5 Box et al. GM-CSF GM-CSF A) B) * * concentration (pg/ml) concentration (pg/ml) * PJS PJR PJS PJR PJS PJR PJS PJR PJS PJR PJS PJR S2 R2 S2 R2 S2 R2 S2 R2 S2 R2 S2 R2 gefitinib gefitinib gefitinib gefitinib gefitinib gefitinib con con con con con con C) IL-8 D) IL-8 concentration (pg/ml) concentration (pg/ml) E) F) TIMP-1 TIMP-1 concentration (pg/ml) concentration (pg/ml)

6. Supplementary Fig. S6 Box et al.

7. Supplementary Fig. S7 Box et al. A) IL-8 concentration (pg/ml) patient number B) TIMP-1 concentration (ng/ml) patient number

8. Supplementary Fig. S7 (contd.) Box et al. C) VEGF-A concentration (pg/ml) patient number

9. Supplementary Fig. S8 Box et al. A) B)